WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 28, 2005--Interleukin Genetics, Inc. (AMEX: ILI) is pleased to announce that effective December 28, 2005 its common shares are listed on the American Stock Exchange(R) (Amex(R)) under the ticker symbol ILI. Philip R. Reilly, Chief Executive Officer of Interleukin Genetics, Inc. said, "We are very pleased to be listed on the Amex. This event will help maintain liquidity in the trading of our stock and provide us with greater exposure to the capital markets."
